Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

- Read more about Scientists light on how to make chromosomes from DNA
Researchers at the University of Tokyo have discovered a long-overlooked process important for converting a long, string-like DNA molecule into a chromosome. This finding gives us a better understanding of the mechanism of how cells store safely genetic material, DNA.
- Read more about JP Nadda holds review meeting on JE outbreak in Assam
Shri J P Nadda, Minister of Health and Family Welfare held a review meeting with senior officials of Health Ministry in the backdrop of recent outbreak of Japanese Encephalitis (JE) in Assam. He stated that the Director General of Health Services has been directed to immediately rush a team of experts to Assam to assist and advise the State health authorities in clinical management of the cases.
- Read more about Biogen looking to enhance research and the development of new PD treatments
Biogen and the Parkinson’s Institute and Clinical Center announced the formation of a strategic alliance focused on enhancing the understanding of the underlying biology of Parkinson’s disease (PD) and the creation of novel tools and programs that could accelerate research and the development of new PD treatments. The agreement will combine the unique clinical expertise and data of the Institute with Biogen’s focus on neurodegenerative disease and approach to clinical development.
- Read more about Boehringer joined with Hanmi to develop EGFR targeted therapy in lung cancer
Boehringer Ingelheim and Hanmi Pharmaceutical Co. Ltd today announced an exclusive license and collaboration agreement for the development and global commercialisation rights, except South Korea, China and Hong Kong, of HM61713, a novel 3rd generation EGFR targeted therapy for the treatment of EGFR mutation positive lung cancer. Under the terms of the agreement Hanmi will receive an initial payment of USD 50 million and is entitled to potential milestone payments of USD 680 million plus tiered double-digit royalties on future net sales. The agreement is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act, similar requirements outside the U.S., and other customary closing conditions.
- Read more about Poverty show negative effect on Kids Brain Development, Learning Capacity and Nurturing Ability
Children born and raised in poverty can experience long term negative effects in brain development, according to a recent study. "Early childhood interventions to support a nurturing environment for these children must now become our top public health priority for the good of all," said Dr. Luby in JAMA Pediatrics.
- Read more about New Malaria Drug may stop the deadly disease
Malaria is caused by infection with the parasite Plasmodium falciparum (Pf). According to the World Health Organization (WHO) malaria currently infects more than 200 million people worldwide and accounts for more than 500,000 deaths per year. Scientists have now developed a new drug that shows hope for stopping the deadly malaria. The study is published in the Journal of Experimental Medicine.
- Read more about Incoming events expectations may shape infants' developing Brains
A new research conducted at the University of British Columbia shows that infants can use their expectations about the world to rapidly shape their developing brains. The research published online in the Proceedings of the National Academy of Sciences.
- Read more about Glenmark introduce third generation oral anti diabetic agent Teneligliptin priced at Rs. 19.90 per tab
In India Glenmark Pharmaceuticals has now introduced its new third generation oral anti diabetic agent Teneligliptin for type-2 diabetes at an affordable price of Rs. 19.90 per tablet. The first pan India launch of Teneligliptin under two brands: Ziten and Zita Plus took place in Bengaluru. The molecule gliptin comes under the category of DPP-4 inhibitors, which is backed by scientific data as being safe, well tolerated, weight neutral with low risk of hypoglycemia.

[adsense:336x280:8701650588]
- Read more about Remembering Dr Suniti Solomon, a Pioneer in India’s HIV Response
(Business Wire India); Dr Suniti Solomon, the Founding Director of YRG CARE and a board member of India HIV/AIDS Alliance passed away peacefully this morning in Chennai.
- Read more about Allergan to acquire Naurex
Allergan plc, a leading global pharmaceutical company, and Naurex Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging disorders of the central nervous system, today announced that they have entered into a definitive agreement under which Allergan will acquire Naurex in an all-cash transaction. Under the terms of the agreement, Allergan will acquire Naurex for a $560 million upfront payment net of cash acquired, $460 million of which is payable upon the closing of the acquisition and $100 million of which is payable by January of 2016 (or upon the closing if the closing has not occurred by such time), as well as potential R&D success-based and sales-threshold milestone payments. The Company remains committed to de-leveraging to below 3.5x debt-to-EBITDA by the end of the first quarter of 2016.